Preparation and in vitro studies of fixed-dose tablet combination of repaglinide and metformin

被引：0
作者：
Sahin, Sinem [1 ]
Mesut, Burcu [2 ]
Durgun, M. Ezgi [2 ]
Ozcelik, Esher [3 ]
Ozsoy, Yildiz [2 ]
机构：
[1] Onko Kocsel Pharmaceut, Kocaeli, Turkey
[2] Istanbul Univ, Fac Pharm, Pharmaceut Technol Dept, Istanbul, Turkey
[3] Cibali Hlth & Social Secur Ctr, Istanbul, Turkey
来源：
ISTANBUL JOURNAL OF PHARMACY | 2021年 / 51卷 / 01期
关键词：
Fixed-Dose Tablet; Metformin; Repaglinide; TYPE-2; PHARMACOKINETICS; THERAPY; CARE;
D O I：
10.26650/IstanbulJPharm.2020.0070
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background and Aims: The study aimed to design a Fixed-dose tablet formulation of Metformine and Repaglinide. Methods: Wet granulation method was used to prepare tablet formulations. Characterization studies and dissolution studies were performed. Results: A stable formulation was developed according to the requirements of the pharmacopoeia criteria. This new formulsation dissolution results showed that Repaglinide and Metformin HCl dissolved more than 85% from film tablets at 15 minutes. Conclusion: Thus, an alternative product to the market product was developed.
引用
收藏
页码：26 / 34
页数：9
相关论文
共 50 条
  • [21] Fixed-dose single tablet antidiabetic combinations
    Bailey, C. J.
    Day, C.
    DIABETES OBESITY & METABOLISM, 2009, 11 (06) : 527 - 533
  • [22] Fixed combination of repaglinide and metformin in the management of type 2 diabetes
    Moses, Robert
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2009, 2 : 101 - 109
  • [23] Effect of food and tablet-dissolution characteristics on the bioavailability of a linagliptin fixed-dose combination with metformin: evidence from two randomized trials
    Metzmann, Katrin
    Schnell, David
    Jungnik, Arvid
    Ring, Arne
    Theodor, Rudolf
    Hohl, Kathrin
    Meinicke, Thomas
    Friedrich, Christian
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (07) : 549 - 563
  • [24] A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control
    Seufert, Jochen
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 : S39 - S48
  • [25] Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
    Reynolds, Jonathan K.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2009, 2 : 127 - 134
  • [26] Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
    Lee, Sang Won
    Park, Sang-In
    Lee, SeungHwan
    Chung, Jae-Yong
    Yu, Kyung-Sang
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (02) : 117 - 124
  • [27] Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food
    Weller, Stephen
    Chen, Shuguang
    Borland, Julie
    Savina, Paul
    Wynne, Brian
    Piscitelli, Stephen C.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (04) : 393 - 398
  • [28] Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
    Kedia, Rohit
    Kulkarni, Supriya
    Ross, Meredith
    Shivaswamy, Vijay
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 1999 - 2006
  • [29] Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
    Dawra, Vikas Kumar
    Liang, Yali
    Wei, Hua
    Pelletier, Kathleen
    Shi, Haihong
    Hickman, Anne
    Bass, Almasa
    Terra, Steven G.
    Zhou, Susan
    Krishna, Rajesh
    Sahasrabudhe, Vaishali
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (01): : 50 - 61
  • [30] Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology
    Chrysi Koliaki
    John Doupis
    Advances in Therapy, 2012, 29 : 993 - 1004
12345